ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Ghebreyesus T, Deressa W, 2006. Malaria. Berhane Y, Hailemariam D, Kloos H, eds. Epidemiology and Ecology of Health and Disease in Ethiopia. Addis Ababa, Ethiopia: Shama Books, 556–576.
-
2.
Federal Ministry of Health of Ethiopia, 2001. National Strategic Plan for Malaria Prevention and Control in Ethiopia 2001–2005. Available at: http://www.moh.gov.et/index.php. Accessed May 15, 2009.
-
3.
Federal Ministry of Health of Ethiopia, 2004. Malaria Diagnosis and Treatment Guidelines for Health Workers in Ethiopia, 2nd ed. Available at: http://www.moh.gov.et/index.php. Accessed May 15, 2009.
-
4.
Daddi J, Gezahegn T, Ambachew M, Asnakew K, Daniel A, Olusegun B, 2005. Therapeutic efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 82: 391–395.
-
5.
Teklehaimanot A, 1996. Chloroquine-resistant Plasmodium falciparum malaria in Ethiopia. Lancet 328: 127–129.
-
6.
World Health Organization, 2002. Report of WHO Consultation on Monitoring Antimalarial Drug Resistance, WHO/CDS/CSR/EPH/2002.17 and WHO/CDS/RBM/2002.39. Geneva, Switzerland: World Health Organization.
-
7.
Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, 2005. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp. Malar J 4: 20.
-
8.
Lindegardh N, Forslund M, Green MD, Kaneko A, Bergqvist Y, 2002. Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia 55: 5–12.
-
9.
Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL, 1997. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621–626.
-
10.
Tulu A, Webber H, Schellenberg A, Bradley D, 1996. Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R Soc Trop Med Hyg 90: 556–557.
-
11.
Yeshiwondim A, Tekle A, Dengela D, Yohannes A, Teklehaimanot A, 2009. Therapeutic Efficacy of Chloroquine and Chloroquine Plus Primaquine for the Treatment of Plasmodium vivax in Ethiopia. Available at: http://www.sciencedirect.com/science/journal/0001706X. Accessed October 14, 2009.
-
12.
Baird J, Sustriayu N, Basri H, Masbar S, Leksana B, Tjitra E, Dewi R, Khairani M, Wignall F, 1996. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 90: 409–411.
-
13.
Biard J, 2004. Minireview: chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075–4083.
-
14.
Teka H, Petros B, Yamuah Y, Tesfaye G, Ibrahim Elhassan I, Simon Muchohi S, Kokwaro G, Aseffa A, Engers H, 2008. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 7: 220.
-
15.
Ketema T, Bacha K, Birhanu T, Petros P, 2009. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, South-West Ethiopia. Malar J 8: 177.
-
16.
Baird J, Lacy M, Basri H, Barcus M, Maguire J, Bangs M, Gramzinski R, Sismadi P, Krisin, Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff D, Hoffman S, 2001. Randomized, parallel placebo-controlled trail of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33: 1990–1997.
-
17.
Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim J, Nandy A, Guthmann J, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day N, Anderson T, White N, 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927–933.
-
18.
Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q, 2007. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 195: 934–941.
-
19.
Daddi J, Gezahegn T, Ambachew M, Asnakew K, Daniel A, Olusegun B, 2005. Baseline study on the safety and efficacy artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 82: 387–390.
-
20.
Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann J, 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365: 1467–1473.
-
21.
Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, Wilairatana P, Kano S, Ringwald P, Looareesuwan S, 2007. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 45: 111–114.
-
22.
Karunajeewa H, Mueller I, Senn M, Lin E, Law I, Gomorrai S, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett K, Davis T, 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545–2557.
-
23.
Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung R, Laihad F, Ebsworth E, Anstey N, Tjitra N, Price R, 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757–765.
-
24.
Baird K, Basri H, Subuanto B, Fryauff J, McElroy D, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171: 678–682.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 654 | 607 | 76 |
| Full Text Views | 414 | 13 | 1 |
| PDF Downloads | 135 | 8 | 1 |
Confirmed Vivax Resistance to Chloroquine and Effectiveness of Artemether-Lumefantrine for the Treatment of Vivax Malaria in Ethiopia
Ambachew M. Yohannes
Ambachew M. Yohannes
World Health Organization Country Office, Addis Ababa, Ethiopia; Mailman School of Public Health and the Earth Institute, Columbia University, New York, New York; Dalarna University College, Borlänge, Sweden; Global Malaria Program, World Health Organization, Geneva, Switzerland
Search for other papers by Ambachew M. Yohannes in
Current site
Google Scholar
PubMed
Search for other papers by Ambachew M. Yohannes in
Current site
Google Scholar
PubMed
Awash Teklehaimanot
Awash Teklehaimanot
World Health Organization Country Office, Addis Ababa, Ethiopia; Mailman School of Public Health and the Earth Institute, Columbia University, New York, New York; Dalarna University College, Borlänge, Sweden; Global Malaria Program, World Health Organization, Geneva, Switzerland
Search for other papers by Awash Teklehaimanot in
Current site
Google Scholar
PubMed
Search for other papers by Awash Teklehaimanot in
Current site
Google Scholar
PubMed
Yngve Bergqvist
Yngve Bergqvist
World Health Organization Country Office, Addis Ababa, Ethiopia; Mailman School of Public Health and the Earth Institute, Columbia University, New York, New York; Dalarna University College, Borlänge, Sweden; Global Malaria Program, World Health Organization, Geneva, Switzerland
Search for other papers by Yngve Bergqvist in
Current site
Google Scholar
PubMed
Search for other papers by Yngve Bergqvist in
Current site
Google Scholar
PubMed
Pascal Ringwald
Pascal Ringwald
World Health Organization Country Office, Addis Ababa, Ethiopia; Mailman School of Public Health and the Earth Institute, Columbia University, New York, New York; Dalarna University College, Borlänge, Sweden; Global Malaria Program, World Health Organization, Geneva, Switzerland
Search for other papers by Pascal Ringwald in
Current site
Google Scholar
PubMed
Search for other papers by Pascal Ringwald in
Current site
Google Scholar
PubMed
Chloroquine (CQ) is still the drug of choice for the treatment of vivax malaria in Ethiopia, whereas artemether-lumefantrine (AL) is for falciparum malaria. In this setting, clinical malaria cases are treated with AL. This necessitated the need to assess the effectiveness of AL for the treatment of Plasmodium vivax with CQ as a comparator. A total of 57 (80.3%) and 75 (85.2%) cases treated with CQ or AL, respectively, completed the study in an outpatient setting. At the end of the follow-up period of 28 days, a cumulative incidence of treatment failure of 7.5% (95% confidence interval [CI] = 2.9–18.9%) for CQ and 19% (95% CI = 11–31.6%) for AL was detected. CQ resistance was confirmed in three of five CQ treatment failures cases. The effectiveness of AL seems lower than CQ; however, the findings were not conclusive, because the AL evening doses were not supervised.
Author Notes
Authors' addresses: Ambachew M. Yohannes, World Health Organization, Geneva, Switzerland, E-mail: yohannesam@who.int. Awash Teklehaimanot, Mailman School of Public Health and The Earth Institute, Columbia University, New York, NY, E-mail: thawash@ei.columbia.edu. Yngve Bergqvist, Dalarna University College, Borlänge, Sweden, E-mail: ybq@du.se. Pascal Ringwald, Global Malaria Programme, World Health Organization, Geneva, Switzerland, E-mail: ringwaldp@who.int.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Ghebreyesus T, Deressa W, 2006. Malaria. Berhane Y, Hailemariam D, Kloos H, eds. Epidemiology and Ecology of Health and Disease in Ethiopia. Addis Ababa, Ethiopia: Shama Books, 556–576.
-
2.
Federal Ministry of Health of Ethiopia, 2001. National Strategic Plan for Malaria Prevention and Control in Ethiopia 2001–2005. Available at: http://www.moh.gov.et/index.php. Accessed May 15, 2009.
-
3.
Federal Ministry of Health of Ethiopia, 2004. Malaria Diagnosis and Treatment Guidelines for Health Workers in Ethiopia, 2nd ed. Available at: http://www.moh.gov.et/index.php. Accessed May 15, 2009.
-
4.
Daddi J, Gezahegn T, Ambachew M, Asnakew K, Daniel A, Olusegun B, 2005. Therapeutic efficacy of sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 82: 391–395.
-
5.
Teklehaimanot A, 1996. Chloroquine-resistant Plasmodium falciparum malaria in Ethiopia. Lancet 328: 127–129.
-
6.
World Health Organization, 2002. Report of WHO Consultation on Monitoring Antimalarial Drug Resistance, WHO/CDS/CSR/EPH/2002.17 and WHO/CDS/RBM/2002.39. Geneva, Switzerland: World Health Organization.
-
7.
Imwong M, Pukrittayakamee S, Grüner AC, Rénia L, Letourneur F, Looareesuwan S, White NJ, Snounou G, 2005. Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp. Malar J 4: 20.
-
8.
Lindegardh N, Forslund M, Green MD, Kaneko A, Bergqvist Y, 2002. Automated solid-phase extraction for determination of amodiaquine, chloroquine and metabolites in capillary blood on sampling paper by liquid chromatography. Chromatographia 55: 5–12.
-
9.
Baird JK, Leksana B, Masbar S, Fryauff DJ, Sutanihardja MA, Suradi, Wignall FS, Hoffman SL, 1997. Diagnosis of resistance to chloroquine by Plasmodium vivax: timing of recurrence and whole blood chloroquine levels. Am J Trop Med Hyg 56: 621–626.
-
10.
Tulu A, Webber H, Schellenberg A, Bradley D, 1996. Failure of chloroquine treatment for malaria in the highlands of Ethiopia. Trans R Soc Trop Med Hyg 90: 556–557.
-
11.
Yeshiwondim A, Tekle A, Dengela D, Yohannes A, Teklehaimanot A, 2009. Therapeutic Efficacy of Chloroquine and Chloroquine Plus Primaquine for the Treatment of Plasmodium vivax in Ethiopia. Available at: http://www.sciencedirect.com/science/journal/0001706X. Accessed October 14, 2009.
-
12.
Baird J, Sustriayu N, Basri H, Masbar S, Leksana B, Tjitra E, Dewi R, Khairani M, Wignall F, 1996. Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans R Soc Trop Med Hyg 90: 409–411.
-
13.
Biard J, 2004. Minireview: chloroquine resistance in Plasmodium vivax. Antimicrob Agents Chemother 48: 4075–4083.
-
14.
Teka H, Petros B, Yamuah Y, Tesfaye G, Ibrahim Elhassan I, Simon Muchohi S, Kokwaro G, Aseffa A, Engers H, 2008. Chloroquine-resistant Plasmodium vivax malaria in Debre Zeit, Ethiopia. Malar J 7: 220.
-
15.
Ketema T, Bacha K, Birhanu T, Petros P, 2009. Chloroquine-resistant Plasmodium vivax malaria in Serbo town, Jimma zone, South-West Ethiopia. Malar J 8: 177.
-
16.
Baird J, Lacy M, Basri H, Barcus M, Maguire J, Bangs M, Gramzinski R, Sismadi P, Krisin, Ling J, Wiady I, Kusumaningsih M, Jones TR, Fryauff D, Hoffman S, 2001. Randomized, parallel placebo-controlled trail of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis 33: 1990–1997.
-
17.
Imwong M, Snounou G, Pukrittayakamee S, Tanomsing N, Kim J, Nandy A, Guthmann J, Nosten F, Carlton J, Looareesuwan S, Nair S, Sudimack D, Day N, Anderson T, White N, 2007. Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites. J Infect Dis 195: 927–933.
-
18.
Chen N, Auliff A, Rieckmann K, Gatton M, Cheng Q, 2007. Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals. J Infect Dis 195: 934–941.
-
19.
Daddi J, Gezahegn T, Ambachew M, Asnakew K, Daniel A, Olusegun B, 2005. Baseline study on the safety and efficacy artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in Ethiopia. East Afr Med J 82: 387–390.
-
20.
Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, Babigumira J, Kigozi I, Kiguli J, Kyomuhendo J, Ferradini L, Taylor W, Checchi F, Guthmann J, 2005. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 365: 1467–1473.
-
21.
Krudsood S, Tangpukdee N, Muangnoicharoen S, Thanachartwet V, Luplertlop N, Srivilairit S, Wilairatana P, Kano S, Ringwald P, Looareesuwan S, 2007. Clinical efficacy of chloroquine versus artemether-lumefantrine for Plasmodium vivax treatment in Thailand. Korean J Parasitol 45: 111–114.
-
22.
Karunajeewa H, Mueller I, Senn M, Lin E, Law I, Gomorrai S, Oa O, Griffin S, Kotab K, Suano P, Tarongka N, Ura A, Lautu D, Page-Sharp M, Wong R, Salman S, Siba P, Ilett K, Davis T, 2008. A trial of combination antimalarial therapies in children from Papua New Guinea. N Engl J Med 359: 2545–2557.
-
23.
Ratcliff A, Siswantoro H, Kenangalem E, Maristela R, Wuwung R, Laihad F, Ebsworth E, Anstey N, Tjitra N, Price R, 2007. Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet 369: 757–765.
-
24.
Baird K, Basri H, Subuanto B, Fryauff J, McElroy D, Leksana B, Richie TL, Masbar S, Wignall FS, Hoffman SL, 1995. Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine. J Infect Dis 171: 678–682.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 654 | 607 | 76 |
| Full Text Views | 414 | 13 | 1 |
| PDF Downloads | 135 | 8 | 1 |